A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
A phase 2 trial of Pazopanib in renal cell carcinoma, run by Imbioray (Hangzhou) Biomedicine Co., Ltd., now recruiting.
Overview
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma is a phase 2 interventional study registered as NCT07087158 by Imbioray (Hangzhou) Biomedicine Co., Ltd., with 30 participants planned, started 2025-09-08 and due to reach its primary completion in 2026-12-31. Interventions recorded: IBR854, Pazopanib. Conditions listed: Renal Cell Carcinoma (RCC). No results are recorded here; the registry entry is the source.
Setting
A Multicenter, Randomized, Open-Label, Active-Controlled Phase II Study Evaluating the Efficacy and Safety of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Phase
Phase 2
Sponsor
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Registry
Enrolled
30
Similar pages
not linked directly; found by shared links- PathwayRenal cell carcinoma (KEGG map)
Shares Pazopanib, Renal cell carcinoma.
- PathwayThe angiogenic switch & tumour vessels
Shares Pazopanib, Renal cell carcinoma.